A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK).
Powles, T Brown, J Larkin, J Jones, R Ralph, C Hawkins, Robert E Chowdhury, S Boleti, E Bhal, A Fife, K
Powles, T
Brown, J
Larkin, J
Jones, R
Ralph, C
Hawkins, Robert E
Chowdhury, S
Boleti, E
Bhal, A
Fife, K
Citations
Altmetric:
Abstract
Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib.
Description
Date
2016-01-22
Publisher
Collections
Keywords
Type
Article
Citation
A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK). 2016: Ann Oncol